BioMarin Pharmaceutical Inc.
BMRN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $776 | $825 | $745 | $747 |
| % Growth | -6% | 10.8% | -0.3% | – |
| Cost of Goods Sold | $140 | $150 | $152 | $136 |
| Gross Profit | $636 | $675 | $594 | $611 |
| % Margin | 82% | 81.8% | 79.7% | 81.8% |
| R&D Expenses | $409 | $161 | $159 | $174 |
| G&A Expenses | $0 | $110 | $104 | $141 |
| SG&A Expenses | $268 | $232 | $206 | $267 |
| Sales & Mktg Exp. | $0 | $122 | $103 | $126 |
| Other Operating Expenses | $5 | $5 | $5 | $10 |
| Operating Expenses | $683 | $398 | $370 | $450 |
| Operating Income | -$47 | $277 | $224 | $161 |
| % Margin | -6% | 33.5% | 30% | 21.6% |
| Other Income/Exp. Net | $20 | $21 | $14 | $8 |
| Pre-Tax Income | -$26 | $298 | $238 | $170 |
| Tax Expense | $4 | $57 | $52 | $45 |
| Net Income | -$31 | $241 | $186 | $125 |
| % Margin | -4% | 29.1% | 24.9% | 16.7% |
| EPS | -0.16 | 1.25 | 0.97 | 0.66 |
| % Growth | -112.8% | 28.9% | 47% | – |
| EPS Diluted | -0.16 | 1.23 | 0.95 | 0.64 |
| Weighted Avg Shares Out | 192 | 191 | 191 | 191 |
| Weighted Avg Shares Out Dil | 192 | 197 | 196 | 197 |
| Supplemental Information | – | – | – | – |
| Interest Income | $18 | $19 | $19 | $18 |
| Interest Expense | $3 | $3 | $3 | $3 |
| Depreciation & Amortization | $18 | $19 | $22 | $24 |
| EBITDA | -$5 | $319 | $263 | $195 |
| % Margin | -0.7% | 38.7% | 35.3% | 26.2% |